Lilly provides update on 2024 revenue guidance, announces 2025 …

22 hours ago · The company anticipates 2025 revenue to be in the range of $58.0 billion to $61.0 billion, growth of 32% at the midpoint compared to expected 2024 revenue. INDIANAPOLIS, …

32%
OFF

Lilly Provides Update On 2024 Revenue Guidance, Announces 2025 …

2 weeks from now

22 hours ago · The company anticipates 2025 revenue to be in the range of $58.0 billion to $61.0 billion, growth of 32% at the midpoint compared to expected 2024 revenue. INDIANAPOLIS, …

lilly.com

32%
OFF

Lilly (LLY) Provides Update On 2024 Revenue Guidance, Announces …

2 weeks from now

22 hours ago · Eli Lilly and Company (NYSE: LLY) today announced that it expects 2024 full-year worldwide revenue to be approximately $45.0 billion, which represents growth of 32% …

streetinsider.com

32%
OFF

6LLY : Eli Lilly Cuts Q4 Revenue Guidance, Expects Around $5.

2 weeks from now

21 hours ago · On Tuesday, Eli Lilly and Co (NYSE: LLY) announced that it expects 2024 full-year worldwide revenue to be approximately $45.0 billion, representing a 32% growth compared to …

benzinga.com

32%
OFF

Eli Lilly Cuts Q4 Revenue Guidance, Expects Around $5.5 Billion …

2 weeks from now

1 day ago · On Tuesday, Eli Lilly and Co (NYSE: LLY) announced that it expects 2024 full-year worldwide revenue to be approximately $45.0 billion, representing a 32% growth compared to …

yahoo.com

$45
OFF

Lilly Provides Update On 2024 Revenue Guidance, Announces 2025 …

2 weeks from now

1 day ago · Eli Lilly (LLY) has updated its revenue guidance for 2024 and announced expectations for 2025. The company projects 2024 full-year revenue of approximately $45.0 …

stocktitan.net

32%
OFF

Eli Lilly's FY24 Revenue To Jump; FY25 Sales Expected To Grow …

2 weeks from now

21 hours ago · -- Eli Lilly said Tuesday revenue is expected to increase year over year for the 12 months ended Dec. 31, 2024. The drugmaker's estimated 2024 revenue is $45 billion, up 32% …

marketscreener.com

32%
OFF

Lilly Provides Update On 2024 Revenue Guidance, Announces 2025 …

2 weeks from now

22 hours ago · The company anticipates 2025 revenue to be in the range of $58.0 billion to $61.0 billion, growth of 32% at the midpoint compared to expected 2024 revenue. INDIANAPOLIS, …

marketscreener.com

32%
OFF

Eli Lilly And Co (LLY) Announces 2024 Revenue Update And 2025 Gu

2 weeks from now

Eli Lilly and Co (LLY, Financial) has released an update on its financial performance, projecting 2024 full-year revenue to reach approximately $45.0 billion, marking a 32% increase from the …

gurufocus.com

60%
OFF

Eli Lilly Stock Slumps On Lowered Sales Forecast - Investopedia

2 weeks from now

18 hours ago · CEO David Ricks said the company expects to produce 60% more doses of the drugs in the first half of 2025 compared to last year. ... "Lilly provides update on 2024 revenue …

investopedia.com

$3
OFF

Lilly Cuts Q4 Revenue View Below Market, Lifts FY24 Outlook; Sees ...

2 weeks from now

22 hours ago · Lilly now expects approximately $3.5 billion for Mounjaro and $1.9 billion for Zepbound. In total, non-incretin revenue grew by 20 percent. However, the company's …

businessinsider.com

$13
OFF

Eli Lilly Issues Q4 2024 Revenue Guidance Below Consensus

2 weeks from now

22 hours ago · Eli Lilly and Company (NYSE:LLY) announced on Tuesday that the pharmaceuticals company expects Q4 2024 revenue to be ~$13.5B. The consensus revenue …

seekingalpha.com

32%
OFF

Lilly Provides Update On 2024 Revenue Guidance, Announces 2025 R

2 weeks from now

1 day ago · The company anticipates 2025 revenue to be in the range of $58.0 billion to $61.0 billion, growth of 32% at the midpoint compared to expected 2024 revenue. INDIANAPOLIS, …

gurufocus.com

45%
OFF

JP Morgan 2025: Eli Lilly Misses 2024 Revenue Estimate By $400m

2 weeks from now

13 hours ago · For Q4 2024, Lilly now expects global revenue of approximately $13.5bn, a 45% increase from Q4 2023. This growth is driven by the strong performance of its incretin-based …

pharmaceutical-technology.com

$13
OFF

Eli Lilly Issues Q4 2024 Revenue Guidance Below Consensus - MSN

2 weeks from now

Eli Lilly and Company (NYSE:LLY) announced on Tuesday that the pharmaceuticals company expects Q4 2024 revenue to be ~$13.5B, about $400M below the lower end of its recently …

msn.com

$13
OFF

Lilly Provides Update On 2024 Revenue Guidance, Announces …

2 weeks from now

22 hours ago · eli lilly and co - q4 2024 revenue expected to be approximately $13.5 billion. eli lilly and co - 2025 revenue guidance between $58 billion and $61 billion. eli lilly and co - 2025 …

tradingview.com

FAQs about Lilly provides update on 2024 revenue guidance, announces 2025 … Coupon?

How much revenue does Eli Lilly expect in Q4 2024?

Eli Lilly and Company (NYSE: LLY) announced on Tuesday that the pharmaceuticals company expects Q4 2024 revenue to be ~$13.5B, about $400M below the lower end of its recently issued financial guidance. The consensus revenue estimate stands at $13.95B. ...

Will Eli Lilly stock remain under a microscope on Wednesday?

Eli Lilly shares could remain under the microscope on Wednesday after falling sharply Tuesday as the pharmaceutical giant lowered its 2024 full-year revenue forecast. This tepid outlook adds to concerns about moderating demand for its flagship weigh-loss drugs. ...

What is LLY's Q4 2024 revenue guidance?

The Q4 2024 revenue guidance represents a 45% growth year-over-year. LLY shares were trading -0.31% pre-market at $795.01. The 2024 revenue is estimated at ~$45.0B, roughly $4B above the midpoint of the first-time 2024 financial guidance. ...

Why are Eli Lilly shares falling?

Eli Lilly shares climbed 32% last year but have slumped more than 16% since October after the company reported third quarter sales of the two drugs below Wall Street’s expectations, prompting concerns about moderating demand. ...

How did non-incretin Revenue perform in 2024?

Overall, non-incretin revenue saw a 20% year-over-year increase. Despite these gains, the company's 2024 revenue forecast fell $400 million, or roughly 3%, short of the guidance provided during its Q3 2024 earnings announcement on October 30. ...

What will Lilly expect from mounjaro & zepbound in 2025?

The rest of our medicines performed within our expectations." Looking ahead, Lilly expects the sales momentum of Mounjaro and Zepbound to continue in 2025, alongside contributions from new medicines and an anticipated 60% increase in salable doses of incretins during the first half of the year. ...